Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality, day 28 -38% Improvement Relative Risk Mortality, day 14 -100% Improvement -11% Hospitalization time -67% c19early.org/cp Sekine et al. NCT04547660 PLACOVID Conv. Plasma RCT LATE Favors conv. plasma Favors control
Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
Sekine et al., European Respiratory Journal, doi:10.1183/13993003.01471-2021, PLACOVID, NCT04547660 (history)
Sekine et al., Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial, European Respiratory Journal, doi:10.1183/13993003.01471-2021, PLACOVID, NCT04547660
Jul 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 160 hospitalized patients in Brazil, showing no significant difference in outcomes with convalescent plasma.
risk of death, 38.5% higher, RR 1.38, p = 0.42, treatment 18 of 80 (22.5%), control 13 of 80 (16.2%), day 28.
risk of death, 100% higher, RR 2.00, p = 0.28, treatment 10 of 80 (12.5%), control 5 of 80 (6.2%), day 14.
risk of no improvement, 10.7% higher, RR 1.11, p = 0.74, treatment 31 of 80 (38.8%), control 28 of 80 (35.0%), day 28.
hospitalization time, 66.7% higher, relative time 1.67, p = 0.87, treatment 80, control 80.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sekine et al., 8 Jul 2021, Randomized Controlled Trial, Brazil, peer-reviewed, 28 authors, study period 15 July, 2020 - 10 December, 2020, average treatment delay 10.0 days, trial NCT04547660 (history) (PLACOVID).
Contact: azavascki@hcpa.edu.br, permissions@ersnet.org.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: EUROPEAN RESPIRATORY JOURNAL ORIGINAL RESEARCH ARTICLE L. SEKINE ET AL. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial Leo Sekine 1,2, Beatriz Arns3, Bruna R. Fabro3, Murillo M. Cipolatt3, Rafael R.G. Machado 4, Edison L. Durigon4,5, Edino Parolo6, José Augusto S. Pellegrini6, Marina V. Viana6, Patrícia Schwarz6, Thiago C. Lisboa6, José Miguel S. Dora 7,8, Julia P. Portich9, Alessandra A. Paz9, Lucia Silla9, Almeri M. Balsan1, Felipe da-Silva Schirmer1, Juliana P.M. Franz1, Luciana M. da-Silveira1, Raquel C. Breunig1, Viviana Petersen1, Monalisa Sosnoski1, Nanci F. Mesquita1, Fabiana Caroline Z. Volpato10,11, Daniel Sganzerla12, Maicon Falavigna12, Regis G. Rosa13 and Alexandre P. Zavascki 3,8 on behalf of PLACOVID Study Group14 1 Transfusion Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 2Medical Sciences Post-Graduate Program, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. 3Infectious Diseases Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 4Dept of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. 5Scientific Platform Pasteur USP, São Paulo, Brazil. 6Critical Care Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 7Internal Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 8Dept of Internal Medicine, Universidade federal do Rio Grande do Sul, Porto Alegre, Brazil. 9Clinical Hematology and Bone Marrow Transplantation Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 10Laboratório de Diagnóstico de SARS-CoV-2, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 11 Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 12Research Projects Office, Hospital Moinhos de Vento (HMV), Porto Alegre, Brazil. 13Intensive Care Service, Hospital Moinhos de Vento, Porto Alegre, Brazil. 14The members of the PLACOVID Study Group are listed in the acknowledgements section. Corresponding author: Alexandre P. Zavascki (azavascki@hcpa.edu.br) Shareable abstract (@ERSpublications) In this open-label, randomised clinical trial, two infusions of convalescent plasma therapy plus standard of care compared to standard of care did not result in higher proportion of clinical improvement on day 28 in patients with severe COVID-19 https://bit.ly/2TXuB6S Cite this article as: Sekine L, Arns B, Fabro BR, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J 2022; 59: 2101471 [DOI: 10.1183/ 13993003.01471-2021]. Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org This article has an editorial commentary: https://doi.org/10.1183/ 13993003.02076-2021 Received: 30 April 2021 Accepted: 16 June 2021 Abstract Background The effects of convalescent plasma (CP) therapy in hospitalised patients with coronavirus disease 2019 (COVID-19) remain uncertain. This study investigates the effect of CP on clinical improvement in these patients. Methods This is an investigator-initiated, randomised, parallel arm, open-label, superiority clinical trial. Patients were randomly (1:1) assigned to two infusions of CP plus standard of care (SOC) or SOC alone...
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit